Science News by @stemcell.com offers 20 regular newsletters with the latest peer-reviewed research, reviews, and industry news delivered straight to your inbox.
💌 Subscribe here: https://bit.ly/47lRBjq
📝 Learn more about the research: bit.ly/3NMcwEJ
📝 Learn more about the research: bit.ly/3NMcwEJ
Join us to work in Nutritional Microbiology and Immunology! 🧪🧫🔬 In coll. with @immunopharmacology.bsky.social we will investigate the effect of #fasting on #inflammation in #heartdisease. Apply today! ⏳️ www.health-life-sciences.de/postdocs/
Join us to work in Nutritional Microbiology and Immunology! 🧪🧫🔬 In coll. with @immunopharmacology.bsky.social we will investigate the effect of #fasting on #inflammation in #heartdisease. Apply today! ⏳️ www.health-life-sciences.de/postdocs/
(macroH2A in magenta, neurons in yellow and F-Actin in cyan)
(macroH2A in magenta, neurons in yellow and F-Actin in cyan)
📚 Read the article to learn more: https://bit.ly/4qQlM9i
📚 Read the article to learn more: https://bit.ly/4qQlM9i
They added DMG-PEG2000-FA to the four-component LNP system and used microfluidic technology to prepare FA-LNP with tumor-targeting groups.
👉 https://bit.ly/3Lrwi7W
They added DMG-PEG2000-FA to the four-component LNP system and used microfluidic technology to prepare FA-LNP with tumor-targeting groups.
👉 https://bit.ly/3Lrwi7W
#OpenAccess
🔓 Learn more: https://go.nature.com/49xKvbj
#OpenAccess
🔓 Learn more: https://go.nature.com/49xKvbj
💡 https://bit.ly/3LcZnnD
💡 https://bit.ly/3LcZnnD
A new @cp-immunity.bsky.social study from @biomedizin.unibas.ch links EBV to early MS-like lesion formation by showing how B cells can act at the very start of the disease process.
🔗 doi.org/10.1016/j.ce...
@unibas.ch #EBV #MultipleSclerosis
A new @cp-immunity.bsky.social study from @biomedizin.unibas.ch links EBV to early MS-like lesion formation by showing how B cells can act at the very start of the disease process.
🔗 doi.org/10.1016/j.ce...
@unibas.ch #EBV #MultipleSclerosis
Congratulations! 🤩
🗞️ https://bit.ly/45d2frb
Congratulations! 🤩
🗞️ https://bit.ly/45d2frb
👉 https://bit.ly/457t2Fk
👉 https://bit.ly/457t2Fk
👉 https://go.nature.com/3NGmZl6
👉 https://go.nature.com/3NGmZl6
🔗 https://go.nature.com/4sCKKul
🔗 https://go.nature.com/4sCKKul
🆕 https://bit.ly/4baQ56b
🆕 https://bit.ly/4baQ56b
💡 Learn more: https://bit.ly/4jCFfIi
💡 Learn more: https://bit.ly/4jCFfIi
🆕 Check it out: https://bit.ly/49epKTk
🆕 Check it out: https://bit.ly/49epKTk
📖 https://bit.ly/3LlxtWq
📖 https://bit.ly/3LlxtWq
👇 Check it out!
@jci.org | https://bit.ly/3YlTzuV
👇 Check it out!
@jci.org | https://bit.ly/3YlTzuV
🔗 https://bit.ly/4qwlOTE
🔗 https://bit.ly/4qwlOTE
🔎 Take a closer look: https://go.nature.com/495h6X6
🔎 Take a closer look: https://go.nature.com/495h6X6
🔗 https://go.nature.com/4jALBYE
🔗 https://go.nature.com/4jALBYE
Our team will be away next week, so there will be a pause in our regular content.
📯 We'll be back the week of January 5th to deliver newsletters and daily posts.
Our team will be away next week, so there will be a pause in our regular content.
📯 We'll be back the week of January 5th to deliver newsletters and daily posts.
Dr. Alifiani Hartono and team demonstrate that CDC7 is a regulator of tumor progression in #prostate cancer and represents new therapeutic target in advanced prostate cancer. 💊
🔗 https://go.nature.com/3KTvwQQ
Dr. Alifiani Hartono and team demonstrate that CDC7 is a regulator of tumor progression in #prostate cancer and represents new therapeutic target in advanced prostate cancer. 💊
🔗 https://go.nature.com/3KTvwQQ
#FluorescenceFriday 🧠🔬🔥
Image credit to @rehg-j.bsky.social and the @lieberinstitute.bsky.social Circuits Team
#FluorescenceFriday 🧠🔬🔥
Image credit to @rehg-j.bsky.social and the @lieberinstitute.bsky.social Circuits Team